摘要：
近日, 北京大学药学院天然药物及仿生药物全国重点实验室谢海燕教授团队在Cell Reports Medicine杂志发表了题为“Potentiating immunotherapy in ‘immune-cold’ solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering”的研究论文。该研究开发了一种肿瘤特异性的基因工程化表达系统, 通过全方位重塑T细胞抗肿瘤免疫应答, 实现对多种低免疫原性“冷肿瘤”的高效抑制, 并显著提升免疫检查点抑制剂(ICIs)和嵌合抗原受体T细胞(CAR-T)疗法对实体瘤的治疗效果。
Supporting:
北京大学药学院天然药物及仿生药物全国重点实验室. 谢海燕团队研发出“冷肿瘤”特异性的基因免疫治疗新策略[J]. 中国药学(英文版), 2026, 35(2): 204-204.
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The research team of Prof. Haiyan Xie has developed a new gene immunotherapy strategy specific to “immune-cold” solid tumors[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(2): 204-204.
>
>